Companies Pfizer

Pfizer

New York

Total Offices: 10

121,990 Total Employees

Year Founded: 1848

View Website

We're Hiring!

Data & Analytics 5 AI & Machine Learning 5 Cybersecurity 4 Marketing 4 Product Management 4 Engineering 3 HR & Recruiting 2 Program & Project Management 2 Design 1 Finance 1 Operations & Support 1

View all jobs

Pfizer Company Growth, Stability & Outlook in New York

Updated on September 16, 2026

What's the stability & growth outlook for Pfizer?

The New York office is characterized by proximity to a headquarters that combines entrenched market leadership with ongoing investment in a sizable late‑stage pipeline and scaling newer brands. Together, these dynamics suggest the New York location offers a stable, innovation‑focused environment with visible momentum in growth products.

Key Insight for Candidates

Pfizer’s New York office is defined by stability anchored in non‑COVID growth and Seagen‑enabled oncology momentum—management even raised guidance as launched/acquired products delivered double‑digit gains. That means steady investment and clear, pipeline‑focused priorities for employees amid COVID revenue normalization.

Evidence in Action

Guidance Transparency Rhythm — 2026 revenue guidance of $60.5–$62.5B and reaffirmed adjusted EPS of $2.80–$3.00 are communicated company-wide. This steady guidance cadence gives New York teams clear planning guardrails for resourcing, targets, and tradeoffs during the post‑COVID normalization.
Ex‑COVID Growth Tracking — Revenue excluding Comirnaty and Paxlovid grew 5% operationally in Q2 2026, and “launched and acquired products” rose 18% operationally. This focus on ex‑COVID and new‑product metrics helps New York teams prioritize growth engines and celebrate momentum beyond headline totals.

Positive Themes About Pfizer

Strong Market Position & Advantage: The New York headquarters anchors a company widely viewed as top‑tier in global biopharma, with leadership in vaccines and a materially expanded oncology platform after the Seagen acquisition. Feedback suggests this stature gives local teams strong category credibility and commercial reach.
Innovation-Driven Growth: In New York, teams are plugged into an R&D engine advancing a broad late‑stage pipeline across oncology, vaccines, and metabolic disease. Recent updates describe numerous pivotal study starts and increased investment, indicating sustained innovation momentum.
Product Line Growth: Launched and acquired products are posting double‑digit operational gains in recent periods, led by assets like Padcev, Eliquis, the Vyndaqel family, and Lorbrena. This momentum signals that newer brands are scaling and contributing meaningfully to growth.